Article, 2024
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT
British Journal of Haematology,
ISSN
1365-2141,
0007-1048,
Volume 204,
6,
Pages 2365-2377,
10.1111/bjh.19448
Contributors
Onida, Francesco
0000-0002-2991-3474
(Corresponding author)
[1]
Gras, Luuk A
[2]
Ge, Junran
[2]
Koster, Linda
[2]
Hamladji, Rose-Marie
[3]
Byrne, Jenny
[4]
Avenoso, Daniele
0000-0003-4218-4170
[5]
Aljurf, Mahmoud Deeb Saeed
0000-0003-1489-1177
[6]
Robin, Marie
[7]
Hałaburda, Kazimierz
0000-0003-3624-785X
[8]
Passweg, Jakob Robert
0000-0001-7092-3351
[9]
Salmenniemi, Urpu
0009-0002-2053-3384
[10]
Sengeloev, Henrik
[11]
Apperley, Jane F
0000-0002-1710-1794
[12]
Clark, Andrew
[13]
Reményi, Péter
[14]
Morozova, Elena
[15]
Kinsella, Francesca A M
0000-0002-6022-2567
[16]
Lenhoff, Stig
[17]
Ganser, Arnold
[18]
Wu, Ka Lung
[19]
Perez‐Martinez, Antonio
[20]
Hayden, Patrick John
0000-0003-1374-4503
[21]
[22]
Raj, Kavita
[23]
Drozd-Sokołowska, Joanna Ewa
0000-0002-4562-6264
[24]
Ortí, Guillermo
0000-0002-7889-5807
[25]
De Lavallade, Hugues
[26]
Yakoub-Agha, Ibrahim
0000-0003-4524-8782
[27]
[28]
Mclornan, Donal Patrick
0000-0003-1224-091X
[23]
Chalandon, Yves
0000-0001-9341-8104
[29]
[30]
Affiliations
- [1]
University of Milan
[NORA names:
Italy; Europe, EU; OECD];
- [2]
European Society for Blood and Marrow Transplantation
[NORA names:
Netherlands; Europe, EU; OECD];
- [3]
Centre Pierre et Marie Curie, Alger, Algeria
[NORA names:
Miscellaneous; Algeria; Africa];
- [4]
Queen's Medical Centre
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
- [5]
King's College Hospital
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
(... more)
- [6]
King Faisal Specialist Hospital & Research Centre
[NORA names:
Saudi Arabia; Asia, Middle East];
- [7]
Hôpital Saint-Louis
[NORA names:
France; Europe, EU; OECD];
- [8]
Instytut Hematologii i Transfuzjologi
[NORA names:
Poland; Europe, EU; OECD];
- [9]
University Hospital of Basel
[NORA names:
Switzerland; Europe, Non-EU; OECD];
- [10]
Helsinki University Hospital
[NORA names:
Finland; Europe, EU; Nordic; OECD];
- [11]
Rigshospitalet
[NORA names:
Capital Region of Denmark;
Hospital; Denmark; Europe, EU; Nordic; OECD];
- [12]
Imperial College London
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
- [13]
Beatson West of Scotland Cancer Centre
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
- [14]
Dél‐Pesti Centrumkórház, Budapest, Hungary
[NORA names:
Hungary; Europe, EU; OECD];
- [15]
First Pavlov State Medical University of St. Petersburg
[NORA names:
Russia; Europe, Non-EU];
- [16]
University Hospitals Birmingham NHS Foundation Trust
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
- [17]
Skåne University Hospital
[NORA names:
Sweden; Europe, EU; Nordic; OECD];
- [18]
Hannover Medical School
[NORA names:
Germany; Europe, EU; OECD];
- [19]
ZNA Middelheim Hospital
[NORA names:
Belgium; Europe, EU; OECD];
- [20]
Hospital Universitario La Paz
[NORA names:
Spain; Europe, EU; OECD];
- [21]
St. James's Hospital
[NORA names:
Ireland; Europe, EU; OECD];
- [22]
Trinity College Dublin
[NORA names:
Ireland; Europe, EU; OECD];
- [23]
University College Hospital
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
- [24]
Central Clinical Hospital
[NORA names:
Poland; Europe, EU; OECD];
- [25]
Vall d'Hebron Hospital Universitari
[NORA names:
Spain; Europe, EU; OECD];
- [26]
Guy's and St Thomas' NHS Foundation Trust
[NORA names:
United Kingdom; Europe, Non-EU; OECD];
- [27]
Centre Hospitalier Universitaire de Lille
[NORA names:
France; Europe, EU; OECD];
- [28]
University of Lille
[NORA names:
France; Europe, EU; OECD];
- [29]
University Hospital of Geneva
[NORA names:
Switzerland; Europe, Non-EU; OECD];
- [30]
University of Geneva
[NORA names:
Switzerland; Europe, Non-EU; OECD]
(less)
Abstract
Allogeneic haematopoietic cell transplantation (allo-HCT) remains an option for tyrosine kinase inhibitor-resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high-risk patients with advanced disease phases. In this European Society for Blood and Marrow Transplantation (EBMT) registry-based study of 1686 CML patients undergoing first allo-HCT between 2012 and 2019, outcomes were evaluated according to donor type, particularly focusing on mismatched related donors (MMRDs). Median age at allo-HCT was 46 years (IQR 36-55). Disease status was CP1 in 43%, second CP (CP2) or later in 27%, accelerated phase in 12% and blast crisis in 18%. Donor type was matched related (MRD) in 39.2%, MMRD in 8.1%, matched unrelated (MUD) in 40.2%, and mismatched unrelated (MMUD) in 12.6%. In 4 years, overall survival (OS) for MRD, MMRD, MUD and MMUD was 61%, 56%, 63% and 59% (p = 0.21); relapse-free survival (RFS) was 48%, 42%, 52% and 46% (p = 0.03); cumulative incidence of relapse (CIR) was 33%, 37%, 27% and 30% (p = 0.07); non-relapse mortality (NRM) was 19%, 21%, 21% and 24% (p = 0.21); and graft-versus-host disease (GvHD)-free/relapse-free survival (GRFS) was 16%, 18%, 22% and 15% (p = 0.05) respectively. On multivariate analysis, MMRD use associated with longer engraftment times and higher risk of graft failure compared to MRD or MUD. There was no statistical evidence that MMRD use associated with different OS, RFS and incidence of GvHD compared to other donor types.
Keywords
CP,
CP1,
CP2,
EBMT,
European,
European Society for Blood,
GVHD,
MMUD,
MRD,
Ph+,
Ph+ chronic myeloid leukemia,
Working Party,
accelerated phase,
advanced disease phase,
age,
allo-HCT,
allogeneic haematopoietic cell transplantation,
analysis,
blast,
blast crisis,
blood,
cell transplantation,
chronic myeloid leukemia,
chronic myeloid leukemia patients,
chronic phase,
chronically,
crisis,
cumulative incidence,
cumulative incidence of relapse,
disease,
disease phase,
disease status,
donor,
donor type,
engraftment time,
evidence,
failure,
graft failure,
graft-versus-host,
graft-versus-host disease (GVHD)-free/relapse-free survival,
haematopoietic cell transplantation,
high risk,
high-risk patients,
higher risk of graft failure,
incidence,
incidence of GVHD,
incidence of relapse,
leukemia,
median age,
mismatched related donor,
mortality,
mud,
multivariate analysis,
myeloid leukemia,
non-relapse mortality,
outcomes,
overall survival,
parties,
patients,
phase,
registry-based study,
relapse,
relapse-free survival,
related donors,
retrospective analysis,
risk of graft failure,
statistical evidence,
status,
study,
survival,
time,
transplantation,
type,
tyrosine,
use,
years
Funders
Data Provider: Digital Science